[
  {
    "sentence": "Four fixed-dose milademetan schedules were planned (Supplementary Fig. 1A).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel A",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Increases in the milademetan dose were guided by the modified continual reassessment method (mCRM), with a planned maximum dose of 160 mg/day (Supplementary Fig. 1B).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel B",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Patients’ disposition and baseline characteristics\nFollowing written informed consent, 14 patients were enrolled in this study, of which four, six, and four were placed in the 90-, 120-, and 160 mg treatment cohorts, respectively (Fig. 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Summary of neutrophil and platelet counts across all visits were presented in supplementary Table 2.Pharmacokinetics\nThe plasma concentration–time profile of milademetan for days 1 and 14 of cycle 1 in the QD 14/28-day schedule is shown in Fig. 2.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The best percent change of blast count from baseline to the end of treatment by TP53 status at the baseline in each patient’s bone marrow is shown as a waterfall plot (Supplementary Fig. 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "The serum MIC-1 level, in most patients, reached a peak on day 8 or 14 of cycle 1 and then decreased to near baseline levels on day 22 of cycle 1 or later (Fig. 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Four (33.3%) patients had a ≥ 50% reduction in baseline blast count in the bone marrow aspirate (Supplementary Fig. 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Four (33.3%) patients had a ≥ 50% reduction of blast count from baseline in the bone marrow aspirate (Supplementary Fig. 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Four fixed-dose milademetan schedules were planned (Supplementary Fig. 1A).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel A",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Increases in the milademetan dose were guided by the modified continual reassessment method (mCRM), with a planned maximum dose of 160 mg/day (Supplementary Fig. 1B).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel B",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Patients’ disposition and baseline characteristics\nFollowing written informed consent, 14 patients were enrolled in this study, of which four, six, and four were placed in the 90-, 120-, and 160 mg treatment cohorts, respectively (Fig. 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Summary of neutrophil and platelet counts across all visits were presented in supplementary Table 2.Pharmacokinetics\nThe plasma concentration–time profile of milademetan for days 1 and 14 of cycle 1 in the QD 14/28-day schedule is shown in Fig. 2.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The best percent change of blast count from baseline to the end of treatment by TP53 status at the baseline in each patient’s bone marrow is shown as a waterfall plot (Supplementary Fig. 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "The serum MIC-1 level, in most patients, reached a peak on day 8 or 14 of cycle 1 and then decreased to near baseline levels on day 22 of cycle 1 or later (Fig. 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Four (33.3%) patients had a ≥ 50% reduction in baseline blast count in the bone marrow aspirate (Supplementary Fig. 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Four (33.3%) patients had a ≥ 50% reduction of blast count from baseline in the bone marrow aspirate (Supplementary Fig. 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Four fixed-dose milademetan schedules were planned (Supplementary Fig. 1A).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel A",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Increases in the milademetan dose were guided by the modified continual reassessment method (mCRM), with a planned maximum dose of 160 mg/day (Supplementary Fig. 1B).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel B",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Patients’ disposition and baseline characteristics\nFollowing written informed consent, 14 patients were enrolled in this study, of which four, six, and four were placed in the 90-, 120-, and 160 mg treatment cohorts, respectively (Fig. 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Summary of neutrophil and platelet counts across all visits were presented in supplementary Table 2.Pharmacokinetics\nThe plasma concentration–time profile of milademetan for days 1 and 14 of cycle 1 in the QD 14/28-day schedule is shown in Fig. 2.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The best percent change of blast count from baseline to the end of treatment by TP53 status at the baseline in each patient’s bone marrow is shown as a waterfall plot (Supplementary Fig. 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "The serum MIC-1 level, in most patients, reached a peak on day 8 or 14 of cycle 1 and then decreased to near baseline levels on day 22 of cycle 1 or later (Fig. 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Four (33.3%) patients had a ≥ 50% reduction in baseline blast count in the bone marrow aspirate (Supplementary Fig. 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Four (33.3%) patients had a ≥ 50% reduction of blast count from baseline in the bone marrow aspirate (Supplementary Fig. 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Four fixed-dose milademetan schedules were planned (Supplementary Fig. 1A).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel A",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Increases in the milademetan dose were guided by the modified continual reassessment method (mCRM), with a planned maximum dose of 160 mg/day (Supplementary Fig. 1B).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel B",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Patients’ disposition and baseline characteristics\nFollowing written informed consent, 14 patients were enrolled in this study, of which four, six, and four were placed in the 90-, 120-, and 160 mg treatment cohorts, respectively (Fig. 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Summary of neutrophil and platelet counts across all visits were presented in supplementary Table 2.Pharmacokinetics\nThe plasma concentration–time profile of milademetan for days 1 and 14 of cycle 1 in the QD 14/28-day schedule is shown in Fig. 2.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The best percent change of blast count from baseline to the end of treatment by TP53 status at the baseline in each patient’s bone marrow is shown as a waterfall plot (Supplementary Fig. 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "The serum MIC-1 level, in most patients, reached a peak on day 8 or 14 of cycle 1 and then decreased to near baseline levels on day 22 of cycle 1 or later (Fig. 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Four (33.3%) patients had a ≥ 50% reduction in baseline blast count in the bone marrow aspirate (Supplementary Fig. 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Four (33.3%) patients had a ≥ 50% reduction of blast count from baseline in the bone marrow aspirate (Supplementary Fig. 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Four fixed-dose milademetan schedules were planned (Supplementary Fig. 1A).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel A",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Increases in the milademetan dose were guided by the modified continual reassessment method (mCRM), with a planned maximum dose of 160 mg/day (Supplementary Fig. 1B).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel B",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Patients’ disposition and baseline characteristics\nFollowing written informed consent, 14 patients were enrolled in this study, of which four, six, and four were placed in the 90-, 120-, and 160 mg treatment cohorts, respectively (Fig. 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Summary of neutrophil and platelet counts across all visits were presented in supplementary Table 2.Pharmacokinetics\nThe plasma concentration–time profile of milademetan for days 1 and 14 of cycle 1 in the QD 14/28-day schedule is shown in Fig. 2.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The best percent change of blast count from baseline to the end of treatment by TP53 status at the baseline in each patient’s bone marrow is shown as a waterfall plot (Supplementary Fig. 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "The serum MIC-1 level, in most patients, reached a peak on day 8 or 14 of cycle 1 and then decreased to near baseline levels on day 22 of cycle 1 or later (Fig. 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Four (33.3%) patients had a ≥ 50% reduction in baseline blast count in the bone marrow aspirate (Supplementary Fig. 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Four (33.3%) patients had a ≥ 50% reduction of blast count from baseline in the bone marrow aspirate (Supplementary Fig. 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Four fixed-dose milademetan schedules were planned (Supplementary Fig. 1A).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel A",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Increases in the milademetan dose were guided by the modified continual reassessment method (mCRM), with a planned maximum dose of 160 mg/day (Supplementary Fig. 1B).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel B",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Patients’ disposition and baseline characteristics\nFollowing written informed consent, 14 patients were enrolled in this study, of which four, six, and four were placed in the 90-, 120-, and 160 mg treatment cohorts, respectively (Fig. 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Summary of neutrophil and platelet counts across all visits were presented in supplementary Table 2.Pharmacokinetics\nThe plasma concentration–time profile of milademetan for days 1 and 14 of cycle 1 in the QD 14/28-day schedule is shown in Fig. 2.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The best percent change of blast count from baseline to the end of treatment by TP53 status at the baseline in each patient’s bone marrow is shown as a waterfall plot (Supplementary Fig. 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "The serum MIC-1 level, in most patients, reached a peak on day 8 or 14 of cycle 1 and then decreased to near baseline levels on day 22 of cycle 1 or later (Fig. 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Four (33.3%) patients had a ≥ 50% reduction in baseline blast count in the bone marrow aspirate (Supplementary Fig. 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Four (33.3%) patients had a ≥ 50% reduction of blast count from baseline in the bone marrow aspirate (Supplementary Fig. 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Four fixed-dose milademetan schedules were planned (Supplementary Fig. 1A).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel A",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Increases in the milademetan dose were guided by the modified continual reassessment method (mCRM), with a planned maximum dose of 160 mg/day (Supplementary Fig. 1B).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel B",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Patients’ disposition and baseline characteristics\nFollowing written informed consent, 14 patients were enrolled in this study, of which four, six, and four were placed in the 90-, 120-, and 160 mg treatment cohorts, respectively (Fig. 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Summary of neutrophil and platelet counts across all visits were presented in supplementary Table 2.Pharmacokinetics\nThe plasma concentration–time profile of milademetan for days 1 and 14 of cycle 1 in the QD 14/28-day schedule is shown in Fig. 2.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The best percent change of blast count from baseline to the end of treatment by TP53 status at the baseline in each patient’s bone marrow is shown as a waterfall plot (Supplementary Fig. 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "The serum MIC-1 level, in most patients, reached a peak on day 8 or 14 of cycle 1 and then decreased to near baseline levels on day 22 of cycle 1 or later (Fig. 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Four (33.3%) patients had a ≥ 50% reduction in baseline blast count in the bone marrow aspirate (Supplementary Fig. 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Four (33.3%) patients had a ≥ 50% reduction of blast count from baseline in the bone marrow aspirate (Supplementary Fig. 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Four fixed-dose milademetan schedules were planned (Supplementary Fig. 1A).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel A",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Increases in the milademetan dose were guided by the modified continual reassessment method (mCRM), with a planned maximum dose of 160 mg/day (Supplementary Fig. 1B).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel B",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Patients’ disposition and baseline characteristics\nFollowing written informed consent, 14 patients were enrolled in this study, of which four, six, and four were placed in the 90-, 120-, and 160 mg treatment cohorts, respectively (Fig. 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Summary of neutrophil and platelet counts across all visits were presented in supplementary Table 2.Pharmacokinetics\nThe plasma concentration–time profile of milademetan for days 1 and 14 of cycle 1 in the QD 14/28-day schedule is shown in Fig. 2.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The best percent change of blast count from baseline to the end of treatment by TP53 status at the baseline in each patient’s bone marrow is shown as a waterfall plot (Supplementary Fig. 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "The serum MIC-1 level, in most patients, reached a peak on day 8 or 14 of cycle 1 and then decreased to near baseline levels on day 22 of cycle 1 or later (Fig. 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Four (33.3%) patients had a ≥ 50% reduction in baseline blast count in the bone marrow aspirate (Supplementary Fig. 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Four (33.3%) patients had a ≥ 50% reduction of blast count from baseline in the bone marrow aspirate (Supplementary Fig. 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Four fixed-dose milademetan schedules were planned (Supplementary Fig. 1A).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel A",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Increases in the milademetan dose were guided by the modified continual reassessment method (mCRM), with a planned maximum dose of 160 mg/day (Supplementary Fig. 1B).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel B",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Four fixed-dose milademetan schedules were planned (Supplementary Fig. 1A).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel A",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Increases in the milademetan dose were guided by the modified continual reassessment method (mCRM), with a planned maximum dose of 160 mg/day (Supplementary Fig. 1B).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel B",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Four fixed-dose milademetan schedules were planned (Supplementary Fig. 1A).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel A",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Increases in the milademetan dose were guided by the modified continual reassessment method (mCRM), with a planned maximum dose of 160 mg/day (Supplementary Fig. 1B).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel B",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Patients’ disposition and baseline characteristics\nFollowing written informed consent, 14 patients were enrolled in this study, of which four, six, and four were placed in the 90-, 120-, and 160 mg treatment cohorts, respectively (Fig. 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Summary of neutrophil and platelet counts across all visits were presented in supplementary Table 2.Pharmacokinetics\nThe plasma concentration–time profile of milademetan for days 1 and 14 of cycle 1 in the QD 14/28-day schedule is shown in Fig. 2.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The best percent change of blast count from baseline to the end of treatment by TP53 status at the baseline in each patient’s bone marrow is shown as a waterfall plot (Supplementary Fig. 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "The serum MIC-1 level, in most patients, reached a peak on day 8 or 14 of cycle 1 and then decreased to near baseline levels on day 22 of cycle 1 or later (Fig. 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Four (33.3%) patients had a ≥ 50% reduction in baseline blast count in the bone marrow aspirate (Supplementary Fig. 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Patients’ disposition and baseline characteristics\nFollowing written informed consent, 14 patients were enrolled in this study, of which four, six, and four were placed in the 90-, 120-, and 160 mg treatment cohorts, respectively (Fig. 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Following written informed consent, 14 patients were enrolled in this study, of which four, six, and four were placed in the 90-, 120-, and 160 mg treatment cohorts, respectively (Fig. 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Pharmacokinetics\nThe plasma concentration–time profile of milademetan for days 1 and 14 of cycle 1 in the QD 14/28-day schedule is shown in Fig. 2.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The plasma concentration–time profile of milademetan for days 1 and 14 of cycle 1 in the QD 14/28-day schedule is shown in Fig. 2.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The best percent change of blast count from baseline to the end of treatment by TP53 status at the baseline in each patient’s bone marrow is shown as a waterfall plot (Supplementary Fig. 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "The serum MIC-1 level, in most patients, reached a peak on day 8 or 14 of cycle 1 and then decreased to near baseline levels on day 22 of cycle 1 or later (Fig. 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "The best percent change of blast count from baseline to the end of treatment by TP53 status at the baseline in each patient’s bone marrow is shown as a waterfall plot (Supplementary Fig. 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "The best percent change of blast count from baseline to the end of treatment by TP53 status at the baseline in each patient’s bone marrow is shown as a waterfall plot (Supplementary Fig. 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "The serum MIC-1 level, in most patients, reached a peak on day 8 or 14 of cycle 1 and then decreased to near baseline levels on day 22 of cycle 1 or later (Fig. 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "The serum MIC-1 level, in most patients, reached a peak on day 8 or 14 of cycle 1 and then decreased to near baseline levels on day 22 of cycle 1 or later (Fig. 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Four (33.3%) patients had a ≥ 50% reduction in baseline blast count in the bone marrow aspirate (Supplementary Fig. 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Four (33.3%) patients had a ≥ 50% reduction in baseline blast count in the bone marrow aspirate (Supplementary Fig. 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Four (33.3%) patients had a ≥ 50% reduction of blast count from baseline in the bone marrow aspirate (Supplementary Fig. 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Four (33.3%) patients had a ≥ 50% reduction of blast count from baseline in the bone marrow aspirate (Supplementary Fig. 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  }
]